GSK plc

GSK plc ROIC

The Return on Invested Capital (ROIC) of GSK plc (GSK.L) as of Nov 12, 2026 is 16.76 %. In the previous year, Return on Invested Capital (ROIC) was 8.40 % — a change of 99.59% (higher).

ROIC

16.76 %

YoY

99.59%

Last updated:

Return on Invested Capital (ROIC) of GSK plc is 2025 16.76 % . Return on Invested Capital (ROIC) of GSK plc was 2024 8.40 % . It decreases by 99.59% higher compared to the previous year.

The GSK plc ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
12.14 GBP
Jan 1, 2019
11.08 GBP
Jan 1, 2020
13.77 GBP
Jan 1, 2021
11.18 GBP
Jan 1, 2022
47.35 GBP
Jan 1, 2023
15.71 GBP
Jan 1, 2024
8.40 GBP
Jan 1, 2025
16.76 GBP
The GSK plc ROIC history
YEARROICYoY
16.76 %+99.59%
8.40 %-46.54%
15.71 %-66.82%
47.35 %+323.61%
11.18 %-18.85%
13.77 %+24.29%
11.08 %-8.71%
12.14 %+34.87%
9.00 %+96.53%
4.58 %-88.18%
38.73 %+223.87%
11.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Return on Invested Capital (ROIC) of GSK plc is 16.76 % in 2025.

Return on Invested Capital (ROIC) of GSK plc changed from 8.40 % to 16.76 %, representing a 99.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) GSK plc since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — GSK plc

All Key Metrics — GSK plc